

Table 1 Clinicopathologic Variables of Patients with a Late Event

	Late Recurrence (n=14)	Late SMN (n=14)	Late Death (n=2)	No Event (n=1,007)
Time To Event (years)				
Mean	6.4	7.6	9.4	8.2
Median	5.7	7.4	9.4	8.0
Range	5.0, 11.3	5.1, 11.0	7.9, 11.0	5.0, 14.8
Age (years), n (%)				
<1	0 (0.0%)	0 (0.0%)	0 (0.0%)	37 (3.7%)
1-9	13 (92.9%)	12 (85.7%)	2 (100.0%)	706 (70.1%)
>=10	1 (7.1%)	2 (14.3%)	0 (0.0%)	264 (26.2%)
Gender, n (%)				
Male	8 (57.1%)	10 (71.4%)	0 (0.0%)	628 (62.4%)
Female	6 (42.9%)	4 (28.6%)	2 (100.0%)	379 (37.6%)
Histology, n (%)				
ARMS	2 (14.3%)	2 (14.3%)	0 (0.0%)	197 (19.6%)
ERMS	8 (57.1%)	8 (57.1%)	1 (50.0%)	523 (51.9%)
BRMS	3 (21.4%)	1 (7.1%)	0 (0.0%)	121 (12.0%)
NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	29 (2.9%)
Spindle cell	1 (7.1%)	2 (14.3%)	0 (0.0%)	121 (12.0%)
Other	0 (0.0%)	1 (7.1%)	0 (0.0%)	2 (0.2%)
Mixed RMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (1.3%)
Unknown	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (0.1%)
Primary Site, n (%)				
Unfavorable	8 (57.1%)	6 (42.9%)	1 (50.0%)	452 (44.9%)
Favorable	5 (35.7%)	8 (57.1%)	0 (0.0%)	532 (52.8%)
Other	1 (7.1%)	0 (0.0%)	0 (0.0%)	22 (2.2%)
Unknown	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (0.1%)
Size, n (%)				
<=5 cm	8 (57.1%)	6 (42.9%)	0 (0.0%)	627 (62.3%)
>5 cm	6 (42.9%)	8 (57.1%)	2 (100.0%)	380 (37.7%)
Tumor Invasiveness, n (%)				
Yes T1	8 (57.1%)	10 (71.4%)	0 (0.0%)	686 (68.1%)
No T2	6 (42.9%)	4 (28.6%)	1 (50.0%)	319 (31.7%)
Unknown	0 (0.0%)	0 (0.0%)	1 (50.0%)	2 (0.2%)
Nodal Involvement, n (%)				
No, N0	11 (78.6%)	12 (85.7%)	1 (50.0%)	848 (84.2%)
Yes, N1	3 (21.4%)	1 (7.1%)	0 (0.0%)	145 (14.4%)
Not Evaluated/Unknown	0 (0.0%)	1 (7.1%)	1 (50.0%)	14 (1.4%)
Group, n (%)				
I	2 (14.3%)	1 (7.1%)	0 (0.0%)	230 (22.8%)
II	2 (14.3%)	2 (14.3%)	0 (0.0%)	190 (18.9%)
III	6 (42.9%)	9 (64.3%)	0 (0.0%)	520 (51.6%)
IV	4 (28.6%)	2 (14.3%)	1 (50.0%)	66 (6.6%)
Unknown	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (0.1%)
Stage, n (%)				
Favorable Site, M0	6 (42.9%)	6 (42.9%)	0 (0.0%)	523 (51.9%)
Other Site, any T, N0, M0	2 (14.3%)	1 (7.1%)	0 (0.0%)	165 (16.4%)
Other Site, any T, N1, M0	2 (14.3%)	5 (35.7%)	0 (0.0%)	251 (24.9%)
Metastases, M1	4 (28.6%)	2 (14.3%)	1 (50.0%)	67 (6.7%)